Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: Street Walker who wrote (590)	11/14/1998 2:44:00 PM
From: LTK007	Read Replies (1) \| Respond to of 752

SW I have noted that this stocks bullish TA commences about the time of this press release--which you have surely seen--but I post for people just coming to the thread---this patent I suspect has real value longterm value--regards when gets to 9--I like to think a month or less:) ---we don't have to worry about earnings until January- --BTW I found out that Advanced Cellular is actually a subsidiary of a chicken farm a Maine,called AVIAN FARM Genzyme Transgenics Receives United States Patent for Transgenic Antibody Production FRAMINGHAM, Mass., Oct. 27 /PRNewswire/ -- Genzyme Transgenics Corporation (Nasdaq: GZTC - news) was today granted U.S. Patent 5,827,690 ''Transgenic Production of Antibodies in Milk'' by the United States Patent and Trademark Office. The patent grants Genzyme Transgenics exclusive rights to the transgenic production of immunoglobulins in commercially useful levels in the milk of mammals. ''This patent gives Genzyme Transgenics a broad proprietary position in transgenic production of monoclonal and other types of assembled antibodies,'' said Sandra Nusinoff Lehrman, president and chief executive officer of Genzyme Transgenics. ''We believe that transgenic production is uniquely suited to commercialization of therapeutic antibodies, especially those administered in large doses for chronic diseases. Genzyme Transgenics intends to leverage its scientific expertise, production experience and patent position to continue to grow its antibody programs.'' Currently, several hundred monoclonal antibodies are in preclinical and clinical development for disorders including heart disease, cancer, rheumatoid arthritis, and infectious diseases, including AIDS. Genzyme Transgenics has produced several antibodies in the milk of transgenic mice and/or goats at commercially useful levels of expression. These include transgenic versions of several antibodies, currently produced by conventional tissue culture methods, which have entered clinical trials for cancer, autoimmune disease and human immune deficiency virus (HIV). The company anticipates that the first transgenically-produced version of a therapeutic antibody, being developed for rheumatoid arthritis in collaboration with BASF Corporation, will enter bridging human clinical trials in 1999. Genzyme Transgenics Corporation applies transgenic technology to enable the development and production of recombinant proteins, particularly monoclonal antibodies, for medical uses. Primedica Corporation, Genzyme Transgenics' wholly owned subsidiary, provides preclinical development and testing services to pharmaceutical, biotechnology, medical device and other companies. Genzyme Transgenics Corporation is also developing idiotypic vaccines in collaboration with the National Cancer Institute. Genzyme General owns approximately 41% of the outstanding common stock of Genzyme Transgenics Corporation. Genzyme General [Nasdaq:GENZ - news] develops and markets therapeutic and surgical products and diagnostic products and services. A division of the biotechnology and health care products company, Genzyme Corp., Genzyme General has its own common stock intended to reflect its value and track its performance. The forward-looking statements contained herein reflect the current views of Genzyme Transgenics Corporation's management with respect to future events, including but not limited to the Company's continued ability to produce antibodies and related molecules in large quantities in the milk of transgenic animals, to develop new business related to transgenic production of antibodies, the timing and outcome of clinical trials, and the timing and content of decisions made by the U.S. Food and Drug Administration. SOURCE: Genzyme Transgenics Corporation